A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2008

• Venue

  NeuroImage

• Publication date

  2008-04-15

• Fields of study

  Medicine, Computer Science, Psychology

• Identifiers
  DOI 10.1016/j.neuroimage.2008.01.030PMID 18313943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches

  2007cited by this paper
• Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer’s disease

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data

  2007cited by this paper
• A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.

  2007cited by this paper
• Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment

  2007cited by this paper
• [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain.

  2007cited by this paper
• Serotonin 1A receptors in the living brain of Alzheimer's disease patients.

  2006influential reference
• A multiresolution image based approach for correction of partial volume effects in emission tomography

  2006cited by this paper
• Evaluation of PET Tracer Binding Recovered by Partial Volume Correction Technique in Case of Hippocampus Atrophy

  2006cited by this paper
• A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging.

  2005cited by this paper
• Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD

  2005cited by this paper
• Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG

  2004cited by this paper
• Occupancy of Agonist Drugs at the 5-HT1A Receptor

  2004cited by this paper
• Medial temporal lobe function and structure in mild cognitive impairment

  2004cited by this paper
• Increased hippocampal neurogenesis in Alzheimer's disease

  2003cited by this paper
• Modeling [18F]MPPF Positron Emission Tomography Kinetics for the Determination of 5-Hydroxytryptamine(1A) Receptor Concentration with Multiinjection

  2002cited by this paper
• Nuclear Science Symposium Medical Imaging Conference

  2002cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• Patterns of brain activation in people at risk for Alzheimer's disease.

  2000cited by this paper
• Quantitative imaging of 5-HT(1A) receptor binding in healthy volunteers with [(18)f]p-MPPF.

  2000cited by this paper
• L'évaluation des troubles de la mémoire

  2000cited by this paper
• ANIMAL+INSECT: Improved Cortical Structure Segmentation

  1999cited by this paper
• The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease

  1999cited by this paper
• High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635.

  1998cited by this paper
• Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

  1997cited by this paper
• Differential effects of protein kinase C activation on 5‐HT1A receptor coupling to Ca2+ and K+ currents in rat serotonergic neurones.

  1996cited by this paper
• Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

  1996cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• [Morphological changes in the human cerebral cortex in dementia].

  1991cited by this paper
• [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level].

  1990cited by this paper
• Wechsler memory scale-revised

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• The measurement of pessimism: the hopelessness scale.

  1974cited by this paper

• [18F]Mefway: Imaging Serotonin 5HT1A Receptors in Human Postmortem Alzheimer’s and Parkinson’s Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Clinical Applications of PET Imaging in Alzheimer's Disease.

  2025cites this paper
• Deciphering the Functions of Raphe–Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer’s Disease

  2025cites this paper
• Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Aβ-Oligomer-Induced Neurotoxicity

  2024cites this paper
• Investigating the spontaneous brain activities of patients with subjective cognitive decline and mild cognitive impairment: an amplitude of low-frequency fluctuation functional magnetic resonance imaging study

  2023cites this paper
• Pathogenesis of Depression in Alzheimer’s Disease

  2023cites this paper
• State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities.

  2022cites this paper
• Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.

  2022cites this paper
• Decreased 5‐HT1A binding in mild Alzheimer's disease—A positron emission tomography study

  2022cites this paper
• Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer’s Disease

  2022cites this paper
• Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics.

  2021cites this paper
• Alterations and interactions of subcortical modulatory systems in Alzheimer's disease.

  2021cites this paper
• PET Agents in Dementia: An Overview.

  2021cites this paper
• Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer’s Disease

  2020cites this paper
• Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

  2020cites this paper
• Cross state-dependency of learning between 5-HT1A and/or 5-HT7 receptor agonists and muscimol in the mouse dorsal hippocampus

  2019cites this paper
• AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems.

  2019cites this paper
• Cognitive Impairment and Dementias.

  2018cites this paper
• The serotonergic system in Alzheimer’s Disease

  2018cites this paper
• Neurological Alterations in Cognitive Impairment

  2017cites this paper
• Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?

  2017cites this paper
• Monoaminergic neuropathology in Alzheimer's disease

  2017influential citation
• Molecular imaging of serotonin degeneration in mild cognitive impairment.

  2017cites this paper
• Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals.

  2016cites this paper
• Comparative assessment of 18F‐Mefway as a serotonin 5‐HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans

  2016cites this paper
• Differential effects of amyloid-beta 1-40 and 1-42 fibrils on 5-HT1A serotonin receptors in rat brain.

  2016cites this paper
• Altered functional brain networks in amnestic mild cognitive impairment: a resting-state fMRI study

  2016cites this paper
• Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

  2016cites this paper
• Serotonin system in Alzheimer's disease : from a molecular and biomarkers perspective

  2016cites this paper
• Cytogenetic Analysis and Screening of ApoE and Neurotransmitters in Alzheimer’s Patients in Tamil Nadu Population

  2016cites this paper
• The role of positron emission tomography imaging in understanding Alzheimer’s disease

  2015cites this paper
• olecular imaging of neuropsychiatric symptoms in Alzheimer ’ s and arkinson ’ s disease

  2014cites this paper
• A Postmortem Study to Compare Agonist and Antagonist 5‐HT1A Receptor‐binding Sites in Alzheimer's Disease

  2014cites this paper
• PET radiotracers for molecular imaging in dementia.

  2014cites this paper
• PET Imaging of the Serotoninergic 5-HT1A System

  2013cites this paper
• Differentially disrupted functional connectivity of the subregions of the inferior parietal lobule in Alzheimer’s disease

  2013cites this paper
• Evaluation of serotonin 5‐HT1A receptors in rodent models using [18F]mefway PET

  2013cites this paper
• Abnormal neural activity and functional connectivity in amnestic Mild cognitive impairmet: A resting state fMRI study

  2013cites this paper
• Current status of positron emission tomography radiotracers for serotonin receptors in humans.

  2013cites this paper
• Association of the interleukin 1 beta gene and brain spontaneous activity in amnestic mild cognitive impairment

  2012cites this paper
• Hippocampal circuitry dysfunction in the 5-HT1A knockout mouse

  2012cites this paper
• Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy

  2012cites this paper
• Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study.

  2012cites this paper
• Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

  2012influential citation
• Communication among neurons.

  2012cites this paper
• The serotonergic system in ageing and Alzheimer's disease.

  2012influential citation
• Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease

  2011cites this paper
• The Reduction of Baseline Serotonin 2A Receptors in Mild Cognitive Impairment is Stable at Two-year Follow-up

  2011cites this paper
• Effects of amyloid-β peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus.

  2011cites this paper
• An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease

  2011cites this paper
• Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

  2011cites this paper
• The Merits of FDDNP-PET Imaging in Alzheimer's Disease

  2011cites this paper
• Frequency-dependent changes in the amplitude of low-frequency fluctuations in amnestic mild cognitive impairment: A resting-state fMRI study

  2011cites this paper
• Positron Emission Tomography in at Risk Patients and in the Progression of Mild Cognitive Impairment to Alzheimer's Disease

  2010cites this paper
• Major depression, cognitive dysfunction and Alzheimer's disease: is there a link?

  2010cites this paper
• Investigating serotonergic function using positron emission tomography: overview and recent findings.

  2010cites this paper
• Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease

  2010cites this paper
• Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT1A receptors in healthy subjects

  2009cites this paper
• Les nouveaux traceurs TEMP et TEP de la démence

  2009cites this paper
• Altered Brain Serotonin Transporter and Associated Glucose Metabolism in Alzheimer Disease

  2009cites this paper
• Vers l'imagerie TEP de la neurotransmission sérotoninergique dans la maladie d'Alzheimer : du radiotraceur au modèle animal.

  2008cites this paper